Detecting and Treating Clostridium Difficile Infections in Patients with Inflammatory Bowel Disease

Gastroenterology Clinics of North America

Volumn 41, Issue 2, 2012, Pages 339-353

  Ananthakrishnan, Ashwin N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clostridium difficile; Crohn disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; BACITRACIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLESTIPOL; COLESTYRAMINE; FIDAXOMICIN; FUSIDIC ACID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ADJUVANT THERAPY; BACTERIAL STRAIN; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; ENTERITIS; ENZYME IMMUNOASSAY; GASTROINTESTINAL SYMPTOM; HUMAN; ILEITIS; ILEOSTOMY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION CONTROL; NEUROPATHY; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; TASTE DISORDER;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 84859652162     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.01.003     Document Type: Review

References (97)

1. Bartlett J.G. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S4-S11.
2. Bartlett J.G., Chang T.W., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978, 298:531-534.
3. Ananthakrishnan A.N., Issa M., Binion D.G. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am 2009, 38:711-728.
4. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
5. Goodhand J.R., Alazawi W., Rampton D.S. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:428-441.
6. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 2009, 33(Suppl 1):S42-S45.
7. Freeman J., Bauer M.P., Baines S.D., et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-549.
8. Kim J., Smathers S.A., Prasad P., et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008, 122:1266-1270.
9. Ananthakrishnan A.N. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011, 8:17-26.
10. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409-415.
11. Pepin J., Valiquette L., Alary M.E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
12. Kuijper E.J., Coignard B., Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006, 12(Suppl 6):2-18.
13. Kutty P.K., Woods C.W., Sena A.C., et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010, 16:197-204.
14. O'Donoghue C., Kyne L. Update on Clostridium difficile infection. Curr Opin Gastroenterol 2011, 27:38-47.
15. Ananthakrishnan A.N., McGinley E.L., Saeian K., et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:976-983.
16. Nguyen G.C., Kaplan G.G., Harris M.L., et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008, 103:1443-1450.
17. Issa M., Vijayapal A., Graham M.B., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:345-351.
18. Rodemann J.F., Dubberke E.R., Reske K.A., et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:339-344.
19. Bolton R.P., Sherriff R.J., Read A.E. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease?. Lancet 1980, 1:383-384.
20. Gryboski J.D. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr 1991, 13:39-41.
21. Meyer A.M., Ramzan N.N., Loftus E.V., et al. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004, 38:772-775.
22. Mylonaki M., Langmead L., Pantes A., et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004, 16:775-778.
23. Jodorkovsky D., Young Y., Abreu M.T. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010, 55:415-420.
24. Pascarella F., Martinelli M., Miele E., et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009, 154:854-858.
25. Wultanska D., Banaszkiewicz A., Radzikowski A., et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis 2010, 29:1264-1270.
26. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18:247-263.
27. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7:526-536.
28. Giesemann T., Egerer M., Jank T., et al. Processing of Clostridium difficile toxins. J Med Microbiol 2008, 57:690-696.
29. Drudy D., Harnedy N., Fanning S., et al. Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect 2007, 13:298-304.
30. Rupnik M., Grabnar M., Geric B. Binary toxin producing Clostridium difficile strains. Anaerobe 2003, 9:289-294.
31. Schwan C., Stecher B., Tzivelekidis T., et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009, 5:e1000626.
32. Pepin J., Valiquette L., Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005, 173:1037-1042.
33. Clements A.C., Magalhaes R.J., Tatem A.J., et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10:395-404.
34. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
35. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
36. Bauer M.P., Notermans D.W., van Benthem B.H., et al. Final results of the first pan-European Clostridium difficile infection survey. 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 10-13 April, 2010 2010.
37. Bauer M.P., Notermans D.W., van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
38. Bossuyt P., Verhaegen J., Van Assche G., et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis 2009, 3:4-7.
39. Goorhuis A., Bakker D., Corver J., et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47:1162-1170.
40. Owens R.C., Donskey C.J., Gaynes R.P., et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S19-S31.
41. Kelly C.P. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA 2009, 301:954-962.
42. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002, 346:334-339.
43. Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S12-S18.
44. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
45. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1432-1442.
46. Jen M.H., Saxena S., Bottle A., et al. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:1322-1331.
47. Dial S., Alrasadi K., Manoukian C., et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, 171:33-38.
48. Arif M., Weber L.R., Knox J.F., et al. Patterns of proton pump inhibitor use in Inflammatory Bowel disease and concomitant risk of Clostridium difficile infection. Gastroenterology 2007, 132:A513.
49. Kelly C.P., Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011, 60(Pt 8):1070-1079.
50. Powell N., Jung S.E., Krishnan B. Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent?. Gut 2008, 57:1183-1184. author reply 1184.
51. Butala P., Divino C.M. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surg 2010, 200:131-135.
52. Greenstein A.J., Byrn J.C., Zhang L.P., et al. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 2008, 143:623-629.
53. Henrich T.J., Krakower D., Bitton A., et al. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009, 15:415-422.
54. Fekety R., Shah A.B. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993, 269:71-75.
55. Kelly C.P., LaMont J.T. Clostridium difficile infection. Annu Rev Med 1998, 49:375-390.
56. Ben-Horin S., Margalit M., Bossuyt P., et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis 2010, 4:194-198.
57. Chiplunker A., Ananthakrishnan A.N., Beaulieu D.B., et al. Long-term impact of Clostridium difficile on inflammatory bowel disease. Gastroenterology 2009, 136(Suppl 1):S1145.
58. Clayton E.M., Rea M.C., Shanahan F., et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009, 104:1162-1169.
59. Shen B.O., Jiang Z.D., Fazio V.W., et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008, 6:782-788.
60. Kim J.H., Muder R.R. Clostridium difficile enteritis: a review and pooled analysis of the cases. Anaerobe 2011, 17:52-55.
61. Lundeen S.J., Otterson M.F., Binion D.G., et al. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg 2007, 11:138-142.
62. Causey M.W., Spencer M.P., Steele S.R. Clostridium difficile enteritis after colectomy. Am Surg 2009, 75:1203-1206.
63. Lavallee C., Laufer B., Pepin J., et al. Fatal Clostridium difficile enteritis caused by the BI/NAP1/027 strain: a case series of ileal C. difficile infections. Clin Microbiol Infect 2009, 15:1093-1099.
64. Miller D.L., Sedlack J.D., Holt R.W. Perforation complicating rifampin-associated pseudomembranous enteritis. Arch Surg 1989, 124:1082.
65. Vesoulis Z., Williams G., Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. Dis Colon Rectum 2000, 43:551-554.
66. Yee H.F., Brown R.S., Ostroff J.W. Fatal Clostridium difficile enteritis after total abdominal colectomy. J Clin Gastroenterol 1996, 22:45-47.
67. McFarland L.V. Renewed interest in a difficult disease: Clostridium difficile infections-epidemiology and current treatment strategies. Curr Opin Gastroenterol 2009, 25:24-35.
68. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
69. Crobach M.J., Dekkers O.M., Wilcox M.H., et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009, 15:1053-1066.
70. Deshpande A., Pasupuleti V., Patel P., et al. Repeat stool testing to diagnose Clostridium difficile infection using enzyme immunoassay does not increase diagnostic yield. Clin Gastroenterol Hepatol 2011, 9:665-669. e1.
71. Nemat H., Khan R., Ashraf M.S., et al. Diagnostic value of repeated enzyme immunoassays in Clostridium difficile infection. Am J Gastroenterol 2009, 104:2035-2041.
72. Fekety R., Silva J., Kauffman C., et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989, 86:15-19.
73. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983, 2:1043-1046.
74. Wenisch C., Parschalk B., Hasenhundl M., et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996, 22:813-818.
75. Pepin J., Alary M.E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40:1591-1597.
76. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40:1586-1590.
77. Aslam S., Hamill R.J., Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005, 5:549-557.
78. Leffler D.A., Lamont J.T. Treatment of Clostridium difficile-associated disease. Gastroenterology 2009, 136:1899-1912.
79. Zar F.A., Bakkanagari S.R., Moorthi K.M., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
80. Louie T. Results of a phase III trial comparing tolveamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD). Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington DC) 2007, ASM Press, Herndon (VA), [abstract k-4259].
81. Libot A., Issa M., Zadvornova Y., et al. Initial vancomycin monotherapy is associated with higher rates of subsequent Clostridium difficile Infection in inflammatory bowel disease population. Chicago (IL) Digestive Disease Week 2011, [abstract # 992].
82. Ben-Horin S., Margalit M., Bossuyt P., et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol 2009, 7:981-987.
83. Yanai H., Nguyen G.C., Yun L., et al. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: Antibiotics alone or combined antibiotics/immunomodulators?. Inflamm Bowel Dis 2011, 17:1540-1546.
84. Gerding D.N., Muto C.A., Owens R.C. Treatment of Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S32-S42.
85. Herpers B.L., Vlaminckx B., Burkhardt O., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009, 48:1732-1735.
86. Abougergi M.S., Broor A., Cui W., et al. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 2010, 5:E1-E9.
87. Zuckerbraun B., Alverdy J., Simmons R.L. Minimally invasive temporary loop ileostomy, colonic lavage, and intracolonic antegrade vancomycin for severe complicated clostridium difficile disease. American Surgical Association 131st Annual Meeting 2011.
88. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009, 58:403-410.
89. Garey K.W., Sethi S., Yadav Y., et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008, 70:298-304.
90. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97:1769-1775.
91. Johnson S., Schriever C., Patel U., et al. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009, 15:290-291.
92. Issa M., Weber L.R., Brandenburg H., et al. Rifaximin and treatment of recurrent Clostridium difficile infection in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:S469.
93. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
94. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004, 53:882-884.
95. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362:197-205.
96. van Nood E., Speelman P., Kuijper E.J., et al. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?. Euro Surveill 2009, 14.
97. Gerding D.N., Muto C.A., Owens R.C. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S43-S49.